ClinicalTrials.gg
RecruitingNCT07856641Updated Oct 2, 2026

Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients

An observational study in Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionMotor Activity(the registry's first term)UnverifiedIs this wrong?Motor Activity is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by The University of Texas Health Science Center, Houston · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis

02

Conditions studied

  • Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity

Browse trials for

Keywords

  • Blood thinner
  • circadian rhythm
  • Venous thromboembolism (VTE)
03

In context

Motor Activity Unverified

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

This study's planned enrollment of 40 is below the median of 98 across 1,240 observational studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.

Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Compared within Motor Activity, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted at HCA Houston Northwest Medical Center and will include adult trauma patients admitted to the Trauma ICU and Trauma Surgical Floor

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatient admission for acute traumatic injury ≥72 hours
  • Prescribed LMWH subcutaneous for VTE chemoprophylaxis

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Brain hemorrhage or non-survivable injury
  • Chronic Kidney disease ≥ 3b estimated (eGFR) less than 30 interferes with coagulation
  • Chronic liver failure

    •-Acute stimulant use of cocaine and methamphetamine

  • Active VTE or ongoing anticoagulation at admission
  • History of coagulopathy or inherited bleeding disorders
  • Chronic alcohol as defined as a documented diagnosis of alcohol use disorder or alcohol consumption exceeding established risk thresholds (men >14 drinks/week; women >7 drinks/week) within the prior 3-6 months
  • Unmanaged psychiatric conditions as defined as diagnosed psychiatric disorder with evidence of inadequate or no active treatment or documented poor symptom control
  • Neurologic injury involving hypothalamic or circadian regulatory centers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hospitalized Trauma Patients Receiving LMWH Chemoprophylaxis

    Hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis as part of routine clinical care. Participants will have anti-FXa levels and antithrombin III (AT3) activity measured at predefined time points to evaluate potential circadian variation in these measures.

06

What researchers measure

Primary outcomes

  1. Change in anti-factor Xa (anti-FXa) levels

    Time frame: 4 hours after the 3rd LMWH dose (T0), then every 6 hours (T6, T12, T18)

  2. Change in Antithrombin III (AT3) activity

    Time frame: 4 hours after the 3rd LMWH dose (T0), then every 6 hours (T6, T12, T18)

07

Study locations

1 of 1 sites recruiting
  • HCA Houston Northwest Medical Center
    Houston, Texas 77090, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 492 non-industry observational studies under Motor Activity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 502 studies reached it within 22 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Aug 26, 2027
CompletionEst.
Mar 26, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856641
Collaborators
Sigma Theta Tau International Grant; Jerold B. Katz Endowment Fund
Responsible party
Evaline Kihara (Acute Care Nurse Practitioner, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Oct 2, 2026
Start date
Aug 26, 2026
Primary completion
Aug 26, 2027 (estimated)
Completion
Mar 26, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Evaline W Kihara, MSN, APRN, AGACNP-BC, CCRN
Contact
Evaline.W.Kihara@uth.tmc.edu
(713) 500-6362
Nikhil Padhye, PhD
Contact
Nikhil.S.Padhye@uth.tmc.edu
(713) 500-2035
Evaline W Kihara, MSN, APRN, AGACNP-BC, CCRN
principal investigator · The University of Texas Health Science Center, Houston
Shiree Berry, MD
study director · HCA Houston NW Medical center- Trauma Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion